129P Tislelizumab combined with bevacizumab plus nab-paclitaxel single-agent chemotherapy for advanced NSCLC after resistance to EGFR TKIs. (December 2022)

Record Type:
Journal Article
Title:
129P Tislelizumab combined with bevacizumab plus nab-paclitaxel single-agent chemotherapy for advanced NSCLC after resistance to EGFR TKIs. (December 2022)
Main Title:
129P Tislelizumab combined with bevacizumab plus nab-paclitaxel single-agent chemotherapy for advanced NSCLC after resistance to EGFR TKIs
Authors:
Zhou, C.
Xie, X.
Yang, Y.
Lin, X.
Xie, Z.
Zhou, M.
Qin, Y.
Zhang, J.
Abstract:
Is Part Of:
Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Issue Display:
Volume 16, Issue 1 (2022)
Year:
2022
Volume:
16
Issue:
1
Issue Sort Value:
2022-0016-0001-0000
Page Start:
Page End:
Publication Date:
2022-12
Subjects:
Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:
https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:
10.1016/j.iotech.2022.100241 ↗
Languages:
English
ISSNs:
2590-0188
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
24685.xml